Cellular Pharmacodynamics of the Novel Biaryloxazolidinone Radezolid: Studies with Infected Phagocytic and Nonphagocytic cells, UsingStaphylococcus aureus,Staphylococcus epidermidis,Listeria monocytogenes, andLegionella pneumophila
- 1 June 2010
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 54 (6) , 2549-2559
Abstract
Radezolid is a novel biaryloxazolidinone in clinical development which shows improved activity, including against linezolid-resistant strains. In a companion paper (29), we showed that radezolid accumulates about 11-fold in phagocytic cells, with ∼60% of the drug localized in the cytosol and ∼40% in the lysosomes of the cells. The present study examines its activity against (i) bacteria infecting human THP-1 macrophages and located in different subcellular compartments (Listeria monocytogenes, cytosol;Legionella pneumophila, vacuoles;Staphylococcus aureusandStaphylococcus epidermidis, mainly phagolysosomal), (ii) strains ofS. aureuswith clinically relevant mechanisms of resistance, and (iii) isogenic linezolid-susceptible and -resistantS. aureusstrains infecting a series of phagocytic and nonphagocytic cells. Radezolid accumulated to similar levels (∼10-fold) in all cell types (human keratinocytes, endothelial cells, bronchial epithelial cells, osteoblasts, macrophages, and rat embryo fibroblasts). At equivalent weight concentrations, radezolid proved consistently 10-fold more potent than linezolid in all these models, irrespective of the bacterial species and resistance phenotype or of the cell type infected. This results from its higher intrinsic activity and higher cellular accumulation. Time kill curves showed that radezolid's activity was more rapid than that of linezolid both in broth and in infected macrophages. These data suggest the potential interest of radezolid for recurrent or persistent infections where intracellular foci play a determinant role.Keywords
This publication has 59 references indexed in Scilit:
- Role ofrsbUand Staphyloxanthin in Phagocytosis and Intracellular Growth ofStaphylococcus aureusin Human Macrophages and Endothelial CellsThe Journal of Infectious Diseases, 2009
- Cellular Accumulation and Pharmacodynamic Evaluation of the Intracellular Activity of CEM-101, a Novel Fluoroketolide, againstStaphylococcus aureus,Listeria monocytogenes, andLegionella pneumophilain Human THP-1 MacrophagesAntimicrobial Agents and Chemotherapy, 2009
- Listeria monocytogenes — from saprophyte to intracellular pathogenNature Reviews Microbiology, 2009
- Activities of Ceftobiprole and Other Cephalosporins against Extracellular and Intracellular (THP-1 Macrophages and Keratinocytes) Forms of Methicillin-Susceptible and Methicillin-ResistantStaphylococcus aureusAntimicrobial Agents and Chemotherapy, 2009
- Intracellular Activity of Antibiotics against Staphylococcus aureus in a Mouse Peritonitis ModelAntimicrobial Agents and Chemotherapy, 2009
- The Legionella pneumophila replication vacuole: making a cosy niche inside host cellsNature Reviews Microbiology, 2008
- Rχ-01, a New Family of Oxazolidinones That Overcome Ribosome-Based Linezolid ResistanceAntimicrobial Agents and Chemotherapy, 2008
- Restoration of Susceptibility of Intracellular Methicillin-ResistantStaphylococcus aureusto β-Lactams: Comparison of Strains, Cells, and AntibioticsAntimicrobial Agents and Chemotherapy, 2008
- In Vitro Activities of the Rx-01 Oxazolidinones against Hospital and Community PathogensAntimicrobial Agents and Chemotherapy, 2008
- The cell biology ofListeria monocytogenesinfectionJournal of Cell Biology, 2002